Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia

Published real-world studies suggest voriconazole may provide reduced length-of-stay, intravenous (IV) length-of-therapy (LOT), and costs compared to liposomal amphotericin B (LAMB) and caspofungin in invasive aspergillosis (IA) patients. We performed a cost analysis of voriconazole versus LAMB and caspofungin as first-line antifungal treatment for IA among patients with prolonged neutropenia or undergoing bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) from payer perspective in Kingdom of Saudi Arabia (KSA).

Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: AA Thaqafi, M Xue, F Farahat, X Gao, MH Wafy, M Fahti, A Ibrahim, C Charbonneau Source Type: research